方盛制药(603998) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was CNY 436,759,573.82, representing a year-on-year increase of 3.30%[3] - Net profit attributable to shareholders was CNY 63,786,808.29, showing a significant increase of 86.45% compared to the same period last year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses reached CNY 49,170,758.24, up by 100.58% year-on-year[3] - Basic earnings per share for the period was CNY 0.15, reflecting an increase of 88.21% compared to the previous year[3] - The weighted average return on equity was 4.49%, an increase of 1.67 percentage points year-on-year[3] - Total operating revenue for Q1 2023 was CNY 436,759,573.82, an increase of 3.9% compared to CNY 422,803,032.95 in Q1 2022[20] - Net profit for Q1 2023 was CNY 63,037,123.91, up 100.5% from CNY 31,343,677.50 in Q1 2022[22] - Earnings per share for Q1 2023 were CNY 0.15, compared to CNY 0.08 in Q1 2022, representing an increase of 87.5%[22] - The company reported a profit before tax of CNY 72,299,752.37, compared to CNY 35,808,330.41 in Q1 2022, an increase of 101.3%[21] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,983,131,860.61, up 2.09% from the end of the previous year[3] - As of March 31, 2023, the total assets of the company amounted to RMB 2,983,131,860.61, an increase from RMB 2,922,150,136.69 at the end of 2022, reflecting a growth of approximately 2.1%[16] - The company reported a total current liabilities of RMB 952,615,299.33, a decrease from RMB 999,587,401.38, reflecting a reduction of about 4.7%[17] - The company’s total liabilities decreased to RMB 1,255,466,225.60 from RMB 1,297,444,234.03, reflecting a decline of about 3.2%[17] - The total liabilities amounted to CNY 1,392,481,793.06, a slight decrease from CNY 1,414,201,204.10 in the previous year[18] Cash Flow - The company reported a net cash flow from operating activities of -CNY 63,977,691.55, indicating a shift from positive to negative cash flow[3] - Cash inflow from operating activities totaled CNY 378,269,536.20, down from CNY 477,571,424.27 in the previous year, a decrease of 20.8%[24] - The net cash flow from operating activities was -$63.98 million, a decrease from $39.25 million in the previous period[25] - Total cash outflow from operating activities amounted to $442.25 million, slightly up from $438.32 million year-over-year[25] - Cash inflow from investment activities totaled $47.96 million, down from $78.08 million in the previous period[25] - The net cash flow from investment activities was -$55.05 million, compared to -$35.46 million in the previous period[25] - Cash inflow from financing activities was $84.33 million, a decrease from $126.35 million year-over-year[25] - The net cash flow from financing activities was -$79.61 million, compared to a positive $19.10 million in the previous period[25] - The ending cash and cash equivalents balance was $184.79 million, down from $279.62 million in the previous period[25] Equity and Investments - Shareholders' equity attributable to the parent company increased to CNY 1,459,415,824.17, a rise of 4.98% from the previous year[3] - Total equity attributable to shareholders increased to CNY 1,459,415,824.17 from CNY 1,390,129,348.50, reflecting a growth of 5.0%[18] - The company’s long-term equity investments increased to RMB 256,735,406.63 from RMB 252,067,896.85, showing a growth of approximately 1.1%[17] - The company’s goodwill rose to RMB 273,983,187.99 from RMB 246,437,637.43, representing an increase of about 11.2%[17] Operational Changes - The increase in net profit was attributed to enhanced product marketing and academic promotion efforts, with the pharmaceutical sector achieving a revenue growth of 22.63%[5] - The company plans to continue focusing on its "338 major product development plan" to drive further growth and efficiency improvements[5] - The company established a new subsidiary, Guangdong Jida Gene Drug Engineering Research Center Co., Ltd., with a registered capital of RMB 7.3 million, holding a 73% equity stake[12] Costs and Expenses - Total operating costs decreased to CNY 383,173,514.19 from CNY 396,051,045.50, reflecting a reduction of approximately 3.5%[20] - Research and development expenses increased to CNY 17,590,859.46 from CNY 16,913,581.31, indicating a growth of 4.0%[21] - The company paid $76.40 million in employee-related cash payments, compared to $99.56 million in the previous period[25] - The company reported a total tax payment of $59.04 million, an increase from $42.57 million year-over-year[25] - Cash outflow for the acquisition of fixed assets was $55.45 million, up from $40.26 million in the previous period[25]